Olink for neurology applications

Towards a better understanding of neurology and neurological diseases

The inaccessibility of the brain and the relative scarcity of definitive physical parameters for clinical evaluation represent major challenges when it comes to neurological conditions such as neurodegenerative diseases and chronic pain. A better understanding of the biology and the underlying pathophysiology is also required. It is important to search for better fluid-based biomarkers that give physicians effective decision making tools. There is a need for easily accessible biomarkers that can  diagnose and stratify patients as well as signal when patients respond to treatment.

Why Olink?

  • Unique technology for protein biomarker discovery with unparalleled specificity, high sensitivity and high throughput, using minimal sample volume
    • 1 µL for each 96-plex Target panel, or <3 µL for each 384-plex Explore panel depending on the platform used
  • A range of compatible sample types such as plasma, serum, CSF, brain tissue lysates and micro-dialysis fluid
  • Two 96-plex panels Olink Target panels and one Olink Explore 384-plex panel available offering validated and exploratory biomarkers for neurology research
  • A broader library of ~3000 protein assays for larger, exploratory studies (Olink Explore 3072).

Publications

Below you can find a few examples of peer-reviewed articles that have used Olink panels in neurology-related studies.

Cuff S, Merola J, Twohih J, et al. Toll-like receptor linked cytokine profiles in cerebrospinal fluid discriminate neurological infection from sterile inflammation. (2021) Brain Communications, DOI: 10.1093/braincomms/fcaa218
Article link>

Isung J, Granqvist M, Trepci A, et al. Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects. (2021) Scientific Reports, DOI: 0.1038/s41598-021-81306-4
Article link>

Ticau S, Sridharan G, Tsour S, et al. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis. (2021) Neurology, DOI: DOI: 10.1212/WNL.0000000000011090
Article link>

Begum G, Reddy R, Yakoub K, Belli A, Davies D and Di Pietro V. Differential Expression of Circulating Inflammatory Proteins Following Sport-Related Traumatic Brain Injury. (2020) International Journal of Medical Sciences, DOI: 10.3390/ijms21041216
Article link>

Santaella A, Kuiperij HB, van Rumund A, Esselink R, van Gool A, Bloem B and Verbeek  M. Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms. (2020) BMC Neurology, DOI: 10.1186/s12883-020-1608-8
Article link>

Whelan C, Mattsson N, Nagle M, Vijayaraghavan S, Hyde C, Janelidze S, Stomrud E, Lee J, Fitz L, Samad T, Ramaswamy G, Margolin R, Mälarstig A and Hansson O. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. (2019) Acta Neuropathologica Communications, DOI: 10.1186/s40478-019-0795-2
Article link>


Testimonials from our neurology customers:


“I am very pleased with the Olink methodology, which has revealed several new biomarkers in the CSF and plasma from patients with multiple sclerosis. It was of particular interest to be able to detect markers in plasma that reflect neuronal damage, including neurofilament light chains.”

Professor Tomas Olsson, Center for Molecular Medicine, Karolinska Hospital, Stockholm.


Tom-Lanz-Principal-Scientist-Pfizer-Neuroscience-on-olink-neurology-applications
“The Olink panel provided some directions we wouldn’t have considered previously, and is a very appealing strategy for neuroscience projects hoping to identify novel CSF biomarkers.”


Tom Lanz
, Principal Scientist, Pfizer Neuroscience



“Olink’s multiplex immunoassay panels are unique tools for finding new biomarkers and gaining a better understanding of the pathophysiology of diseases, which is something I apply in my own field of pain research.”


Professor Torsten Gordh
, Department of Surgical Sciences, Uppsala University



“Protein signatures can improve our understanding of pathophysiology and disease progression, to better predict clinical outcomes and tailor treatments to match individual patient needs. Olink’s panels require such a small volume of material that it is now possible to analyze temporal profiles of multiple biomarkers of complex disease processes that would be very difficult to examine with other techniques.”

Professor Lars Hillered, Department of  Neuroscience, Uppsala University


Olink’s offering for neurologists

Protein biomarker panels

Olink currently offers two 92-plex protein biomarker panels that are focused on neuroscience and neurological diseases.

  • Olink Target 96 Neurology –  offers a mix of established markers (related to processes such as neural development, axon guidance, synaptic function, or specific conditions such as Alzheimer’s disease), as well as some more exploratory proteins with broader roles in processes such as cellular regulation, immunology, development and metabolism. The panel includes an assay for the key neuro-marker, Tau (Microtubule-associated protein tau, MAPT, Uniprot number P10636)
  • Olink Target 96 Neuro Exploratory – Complementing our NEUROLOGY panel, this panel offers scientists the chance to cast a wider net in the quest to identify new biomarkers and relevant protein signatures in neurology studies, with assays focused on important biological processes such as  axon development, neurogenesis and synapse assembly. The panel includes a high-performance assay for the key neuro-marker, Neurofilament light polypeptide (NFL, Uniprot no. P07196), which is an important marker for degenerative neurological diseases and traumatic brain injury.
  • Olink Explore 384 Neurology – offers simultaneous analysis of 384 protein biomarkers using just 1 µL of biological sample, and all assays are subject to Olink’s strict technical validation and Quality Control procedures. This high level of multiplexing is achieved without any compromise on data quality, thanks to our proprietary Proximity Extension Assay (PEA) technology. The panel panel offers a mix of established markers related to neurobiological processes and neurological diseases (e.g. neural development, axon guidance, synaptic function, or specific conditions such as Alzheimer’s disease), as well as some more exploratory proteins.

Literature

Our Neurology Focus note provides an overview of how Olink’s panels have been used in neurology research and includes several application examples – DOWNLOAD HERE

csf-webinar-thumb

Learn how Olink® technology was successfully used in cerebrospinal fluid to identify biomarkers of cognitive impairment in HIV and Alzheimer’s disease.

Do you want to know more?

Please contact us using the form below:



2947

Biomarker assays

~881 million

Protein data points generated

1049

Publications listed on website

Contact us!